Asefa Gebre
Medical · Carthage, MONPI 1700245628
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 25.4% of the total.
Across 169 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$764
- Lilly USA, LLC$237
- Otsuka America Pharmaceutical, Inc.$229
- Vanda Pharmaceuticals Inc.$212
- Novo Nordisk$169
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$165
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,87595%
- Education$1375%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $764 |
| Lilly USA, LLC | 15 | $237 |
| Otsuka America Pharmaceutical, Inc. | 13 | $229 |
| Vanda Pharmaceuticals Inc. | 9 | $212 |
| Novo Nordisk | 10 | $169 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $165 |
| Medical Device Business Services, Inc. | 1 | $137 |
| Exact Sciences | 7 | $118 |
| Lundbeck LLC | 6 | $117 |
| AstraZeneca | 7 | $108 |
| Globus Medical | 3 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $95 |
| Collegium Pharmaceutical, Inc. | 5 | $81 |
| Indivior Inc. | 4 | $76 |
| Mylan Specialty L.p. | 5 | $66 |
| Apria Healthcare LLC | 2 | $53 |
| Boehringer Ingelheim | 3 | $48 |
| Amgen | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Ardelyx, Inc. | 1 | $28 |
| Braeburn Inc. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Pfizer | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Philips North America LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DERMABOND$137
How this compares
$3,012 in reported general payments places this provider in the 80th percentile of 198 medical providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $81,537 |
| FarxigaDapagliflozin Propanediol | 123 | $66,756 |
| JardianceEmpagliflozin | 120 | $65,554 |
| TrulicityDulaglutide | 55 | $57,628 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $28,479 |
| VraylarCariprazine Hcl | 17 | $27,782 |
| RybelsusSemaglutide | 23 | $22,157 |
| XareltoRivaroxaban | 28 | $18,182 |
| EntrestoSacubitril/Valsartan | 30 | $17,531 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $15,375 |
| LinzessLinaclotide | 25 | $14,004 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $12,810 |
| RexultiBrexpiprazole | 12 | $12,607 |
| VascepaIcosapent Ethyl | 37 | $12,520 |
| MyrbetriqMirabegron | 39 | $11,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $169 | $103,694104 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $108 | $85,500176 claims |
| Boehringer IngelheimJardiance, Synjardy | $48 | $73,548133 claims |
| Lilly USA, LLCTrulicity | $237 | $57,62855 claims |
| AbbVieVraylar, Linzess | $764 | $41,78542 claims |
| Johnson & JohnsonXarelto | $14 | $18,18228 claims |
| NovartisEntresto | $15 | $17,53130 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $229 | $12,60712 claims |
| PfizerEliquis | $17 | $9,76121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 198 medical providers in Missouri.
Other medical in Carthage
- Melanie ChisamSpringfield$92K
- Emily JensenBowling Green$51K
- Sarah WilmsmeyerChesterfield$22K
- Amy MosmanSaint Louis$21K
- Dustin BartlettSpringfield$21K
- Alexa Fider-WhyteSaint Louis$18K
- Megan Isaacson-SchmidSaint Louis$16K
- Erin YoffieSaint Louis$16K
- Corey WhitesidesColumbia$15K
- David WinchellSaint Peters$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.